Researchers Identify CD99L2 Gene Mutation as Cause of Rare Movement Disorder

Researchers at Ruhr-University Bochum have identified a previously unrecognized genetic cause for X-linked spastic ataxia, a rare and debilitating movement disorder. By analyzing the genetic profiles of nearly 3,000 patients suffering from conditions like ataxia and hereditary spastic paraplegia, the team pinpointed harmful mutations in the CD99L2 gene. Previously, this gene was associated exclusively with immune system functions, marking this discovery as a significant shift in our understanding of its biological role.

The study, published in Nature Communications, reveals that CD99L2 is essential for maintaining efficient communication pathways within nerve cells. Specifically, the protein encoded by this gene acts as a critical partner for CAPN1, an enzyme already linked to neurodegenerative conditions. When CD99L2 mutations occur, the interaction with CAPN1 is disrupted, leading to impaired neuronal signaling and the subsequent movement-related symptoms characteristic of spastic ataxia.

This breakthrough underscores the importance of integrating large-scale genomic data with functional neuroscience. By demonstrating that a gene once thought to be immune-specific is actually vital for neurological health, the researchers have provided a new diagnostic target for patients who previously lacked a clear explanation for their symptoms.

Beyond immediate diagnostic benefits, this discovery offers a deeper look into the biological mechanisms of neurodegeneration. By mapping how CD99L2 defects interfere with cellular processes, scientists can better understand the pathways that lead to motor control loss. This research not only paves the way for more accurate genetic testing but also opens new avenues for exploring potential therapeutic interventions for rare neurological diseases.